Heard in the Health and Human Services Interim Committee on 11/19/2025 1

# **Kratom Adjustments**

## 2026 GENERAL SESSION

## STATE OF UTAH

# **Chief Sponsor:**

Sponsor:

LONG TITLE
General Description:
This bill amends provisions related to kratom.
Highlighted Provisions:
This bill:
<ul> <li>repeals the Kratom Consumer Protection Act; and</li> </ul>
<ul> <li>schedules alkaloids found in or derived from kratom as schedule I controlled substances.</li> </ul>
Money Appropriated in this Bill:
None
Other Special Clauses:
None
<b>Utah Code Sections Affected:</b>
AMENDS:
58-37-4, as last amended by Laws of Utah 2025, Chapter 216
REPEALS:
<b>4-45-101</b> , as enacted by Laws of Utah 2019, Chapter 329
<b>4-45-102</b> , as enacted by Laws of Utah 2019, Chapter 329
<b>4-45-103</b> , as enacted by Laws of Utah 2019, Chapter 329
<b>4-45-104</b> , as enacted by Laws of Utah 2019, Chapter 329
<b>4-45-105</b> , as enacted by Laws of Utah 2019, Chapter 329
<b>4-45-106</b> , as enacted by Laws of Utah 2019, Chapter 329
<b>4-45-107</b> , as enacted by Laws of Utah 2019, Chapter 329
4-45-108, as enacted by Laws of Utah 2019, Chapter 329
Be it enacted by the Legislature of the state of Utah:
Section 1. Section <b>58-37-4</b> is amended to read:
58-37-4 . Schedules of controlled substances Schedules I through $V$ Findings

31	(1) There are established five schedules of controlled substances known as Schedules I, II,
32	III, IV, and V which consist of substances listed in this section.
33	(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the
34	official name, common or usual name, chemical name, or brand name designated:
35	(a) Schedule I:
36	(i) Unless specifically excepted or unless listed in another schedule, any of the
37	following opiates, including their isomers, esters, ethers, salts, and salts of
38	isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
39	salts is possible within the specific chemical designation:
40	(A) Acetyl-alpha-methylfentanyl
41	(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
42	(B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
43	(C) Acetylmethadol;
44	(D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
45	(E) Allylprodine;
46	(F) Alphacetylmethadol, except levo-alphacetylmethadol also known as
47	levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
48	(G) Alphameprodine;
49	(H) Alphamethadol;
50	(I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
51	propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
52	(J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
53	piperidinyl]-N-phenylpropanamide);
54	(K) Benzylpiperazine;
55	(L) Benzethidine;
56	(M) Betacetylmethadol;
57	(N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
58	piperidinyl]-N-phenylpropanamide);
59	(O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
60	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
61	(P) Betameprodine;
62	(Q) Betamethadol;
63	(R) Betaprodine;
64	(S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);

65	(T) Clonitazene;
66	(U) Cyclopropyl fentanyl
67	(N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
68	(V) Dextromoramide;
69	(W) Diampromide;
70	(X) Diethylthiambutene;
71	(Y) Difenoxin;
72	(Z) Dimenoxadol;
73	(AA) Dimepheptanol;
74	(BB) Dimethylthiambutene;
75	(CC) Dioxaphetyl butyrate;
76	(DD) Dipipanone;
77	(EE) Ethylmethylthiambutene;
78	(FF) Etizolam
79	(1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
80	(GG) Etonitazene;
81	(HH) Etoxeridine;
82	(II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
83	furan-2-carboxamide);
84	(JJ) Furethidine;
85	(KK) Hydroxypethidine;
86	(LL) Ketobemidone;
87	(MM) Levomoramide;
88	(NN) Levophenacylmorphan;
89	(OO) Methoxyacetyl fentanyl
90	(2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
91	(PP) Morpheridine;
92	(QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
93	(RR) Noracymethadol;
94	(SS) Norlevorphanol;
95	(TT) Normethadone;
96	(UU) Norpipanone;
97	(VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
98	propanamide);

99	(WW) Para-fluoroisobutyryl fentanyl
100	(N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
101	(XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
102	(YY) Phenadoxone;
103	(ZZ) Phenampromide;
104	(AAA) Phenibut;
105	(BBB) Phenomorphan;
106	(CCC) Phenoperidine;
107	(DDD) Piritramide;
108	(EEE) Proheptazine;
109	(FFF) Properidine;
110	(GGG) Propiram;
111	(HHH) Racemoramide;
112	(III) Tetrahydrofuran fentanyl
113	(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
114	(JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
115	(KKK) Tianeptine;
116	(LLL) Tilidine;
117	(MMM) Trimeperidine;
118	(NNN) 3-methylfentanyl, including the optical and geometric isomers
119	(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
120	(OOO) 3-methylthiofentanyl
121	(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
122	(PPP) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also
123	known as U-47700; and
124	(QQQ) 4-cyano CUMYL-BUTINACA.
125	(ii) Unless specifically excepted or unless listed in another schedule, any of the
126	following opium derivatives, their salts, isomers, and salts of isomers when the
127	existence of the salts, isomers, and salts of isomers is possible within the specific
128	chemical designation:
129	(A) Acetorphine;
130	(B) Acetyldihydrocodeine;
131	(C) Benzylmorphine;
132	(D) Codeine methylbromide;

133	(E) Codeine-N-Oxide;
134	(F) Cyprenorphine;
135	(G) Desomorphine;
136	(H) Dihydromorphine;
137	(I) Drotebanol;
138	(J) Etorphine (except hydrochloride salt);
139	(K) Heroin;
140	(L) Hydromorphinol;
141	(M) Methyldesorphine;
142	(N) Methylhydromorphine;
143	(O) Morphine methylbromide;
144	(P) Morphine methylsulfonate;
145	(Q) Morphine-N-Oxide;
146	(R) Myrophine;
147	(S) Nicocodeine;
148	(T) Nicomorphine;
149	(U) Normorphine;
150	(V) Pholcodine; and
151	(W) Thebacon.
152	(iii) Unless specifically excepted or unless listed in another schedule, any material,
153	compound, mixture, or preparation which contains any quantity of the following
154	hallucinogenic substances, or which contains any of their salts, isomers, and salts
155	of isomers when the existence of the salts, isomers, and salts of isomers is possible
156	within the specific chemical designation; as used in this Subsection (2)(a)(iii)
157	only, "isomer" includes the optical, position, and geometric isomers:
158	(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; $\alpha$
159	-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; $\alpha$ -ET; and AET;
160	(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
161	4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
162	(C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
163	2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;
164	2C-B, Nexus;
165	(D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- $\alpha$
166	-methylphenethylamine; 2,5-DMA;

167	(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
168	(F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- $\alpha$
169	-methylphenethylamine; paramethoxyamphetamine, PMA;
170	(G) 5-methoxy-3,4-methylenedioxyamphetamine;
171	(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
172	4-methyl-2,5-dimethoxy- $\alpha$ -methylphenethylamine; "DOM"; and "STP";
173	(I) 3,4-methylenedioxy amphetamine;
174	(J) 3,4-methylenedioxymethamphetamine (MDMA);
175	(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
176	alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE,
177	MDEA;
178	(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
179	N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy
180	MDA;
181	(M) 3,4,5-trimethoxy amphetamine;
182	(N) Bufotenine, some trade and other names: $3-(\beta$
183	-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol;
184	N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
185	(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
186	(P) Dimethyltryptamine, some trade or other names: DMT;
187	(Q) Ibogaine, some trade and other names: 7-Ethyl-6,6β
188	,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]
189	azepino [5,4-b] indole; Tabernanthe iboga;
190	(R) Lysergic acid diethylamide;
191	(S) Marijuana;
192	(T) Mescaline;
193	(U) Parahexyl, some trade or other names:
194	3- Hexyl-1- hydroxy-7, 8, 9, 10- tetra hydro-6, 6, 9- trimethyl-6 H-dibenzo [b,d] pyran;
195	Synhexyl;
196	(V) Peyote, meaning all parts of the plant presently classified botanically as
197	Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any
198	extract from any part of such plant, and every compound, manufacture, salts,
199	derivative, mixture, or preparation of such plant, its seeds or extracts
200	(Interprets 21 USC 812(c), Schedule I(c) (12)):

201	(W) N-ethyl-3-piperidyl benzilate;
202	(X) N-methyl-3-piperidyl benzilate;
203	(Y) Psilocybin;
204	(Z) Psilocyn;
205	(AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
206	(cannabis plant), except for marijuana as defined in Subsection 58-37-2
207	(1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the
208	cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic
209	substances, derivatives, and their isomers with similar chemical structure and
210	pharmacological activity to those substances contained in the plant, such as the
211	following: Δ1 cis or trans tetrahydrocannabinol, and their optical isomers Δ6 cis or
212	trans tetrahydrocannabinol, and their optical isomers $\Delta 3,4$ cis or trans
213	tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
214	substances is not internationally standardized, compounds of these structures,
215	regardless of numerical designation of atomic positions covered;
216	(BB) Ethylamine analog of phencyclidine, some trade or other names:
217	N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
218	N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
219	(CC) Pyrrolidine analog of phencyclidine, some trade or other names:
220	1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
221	(DD) Thiophene analog of phencyclidine, some trade or other names:
222	1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine,
223	TPCP, TCP; and
224	(EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
225	(iv) Unless specifically excepted or unless listed in another schedule, any material
226	compound, mixture, or preparation which contains any quantity of the following
227	substances having a depressant effect on the central nervous system, including its
228	salts, isomers, and salts of isomers when the existence of the salts, isomers, and
229	salts of isomers is possible within the specific chemical designation:
230	(A) Mecloqualone; and
231	(B) Methaqualone.
232	(v) Any material, compound, mixture, or preparation containing any quantity of the
233	following substances having a stimulant effect on the central nervous system,
234	including their salts, isomers, and salts of isomers:

235	(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
236	or 4,5-dihydro-5-phenyl-2-oxazolamine;
237	(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
238	alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
239	(C) Fenethylline;
240	(D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
241	alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
242	alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone;
243	N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432,
244	its salts, optical isomers, and salts of optical isomers;
245	(E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine)
246	(F) N-ethylamphetamine; and
247	(G) N,N-dimethylamphetamine, also known as
248	N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
249	(vi) Any material, compound, mixture, or preparation which contains any quantity of
250	the following substances, including their optical isomers, salts, and salts of
251	isomers, subject to temporary emergency scheduling:
252	(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
253	(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
254	(vii) Unless specifically excepted or unless listed in another schedule, any material,
255	compound, mixture, or preparation which contains any quantity of gamma
256	hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and
257	salts of isomers.
258	(viii) Unless specifically excepted or unless listed in another schedule, any alkaloids
259	found in or derived from Mitragyna speciosa, including synthetic alkaloids,
260	homologs, analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and
261	ethers, when the existence of the isomers, esters, ethers, and salts is possible
262	within the specific chemical designation.
263	(b) Schedule II:
264	(i) Unless specifically excepted or unless listed in another schedule, any of the
265	following substances whether produced directly or indirectly by extraction from
266	substances of vegetable origin, or independently by means of chemical synthesis,
267	or by a combination of extraction and chemical synthesis:
268	(A) Opium and opiate, and any salt, compound, derivative, or preparation of

269	opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene,
270	naloxone, and naltrexone, and their respective salts, but including:
271	(I) Raw opium;
272	(II) Opium extracts;
273	(III) Opium fluid;
274	(IV) Powdered opium;
275	(V) Granulated opium;
276	(VI) Tincture of opium;
277	(VII) Codeine;
278	(VIII) Ethylmorphine;
279	(IX) Etorphine hydrochloride;
280	(X) Hydrocodone;
281	(XI) Hydromorphone;
282	(XII) Metopon;
283	(XIII) Morphine;
284	(XIV) Oxycodone;
285	(XV) Oxymorphone; and
286	(XVI) Thebaine;
287	(B) Any salt, compound, derivative, or preparation which is chemically equivalent
288	or identical with any of the substances referred to in Subsection (2)(b)(i)(A),
289	except that these substances may not include the isoquinoline alkaloids of
290	opium;
291	(C) Opium poppy and poppy straw;
292	(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves,
293	and any salt, compound, derivative, or preparation which is chemically
294	equivalent or identical with any of these substances, and includes cocaine and
295	ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,
296	whether derived from the coca plant or synthetically produced, except the
297	substances may not include decocainized coca leaves or extraction of coca
298	leaves, which extractions do not contain cocaine or ecgonine; and
299	(E) Concentrate of poppy straw, which means the crude extract of poppy straw in
300	either liquid, solid, or powder form which contains the phenanthrene alkaloids
301	of the opium poppy.
302	(ii) Unless specifically excepted or unless listed in another schedule, any of the

303	following opiates, including their isomers, esters, ethers, salts, and salts of
304	isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
305	salts is possible within the specific chemical designation, except dextrorphan and
306	levopropoxyphene:
307	(A) Alfentanil;
308	(B) Alphaprodine;
309	(C) Anileridine;
310	(D) Bezitramide;
311	(E) Bulk dextropropoxyphene (nondosage forms);
312	(F) Carfentanil;
313	(G) Dihydrocodeine;
314	(H) Diphenoxylate;
315	(I) Fentanyl;
316	(J) Isomethadone;
317	(K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
318	levomethadyl acetate, or LAAM;
319	(L) Levomethorphan;
320	(M) Levorphanol;
321	(N) Metazocine;
322	(O) Methadone;
323	(P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
324	(Q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
325	1-diphenylpropane-carboxylic acid;
326	(R) Pethidine (meperidine);
327	(S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
328	(T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
329	(U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
330	(V) Phenazocine;
331	(W) Piminodine;
332	(X) Racemethorphan;
333	(Y) Racemorphan;
334	(Z) Remifentanil; and
335	(AA) Sufentanil.
336	(iii) Unless specifically excepted or unless listed in another schedule, any material,

337	compound, mixture, or preparation which contains any quantity of the following
338	substances having a stimulant effect on the central nervous system:
339	(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
340	(B) Methamphetamine, its salts, isomers, and salts of its isomers;
341	(C) Phenmetrazine and its salts; and
342	(D) Methylphenidate.
343	(iv) Unless specifically excepted or unless listed in another schedule, any material,
344	compound, mixture, or preparation which contains any quantity of the following
345	substances having a depressant effect on the central nervous system, including its
346	salts, isomers, and salts of isomers when the existence of the salts, isomers, and
347	salts of isomers is possible within the specific chemical designation:
348	(A) Amobarbital;
349	(B) Glutethimide;
350	(C) Pentobarbital;
351	(D) Phencyclidine;
352	(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
353	1-piperidinocyclohexanecarbonitrile (PCC); and
354	(F) Secobarbital.
355	(v)(A) Unless specifically excepted or unless listed in another schedule, any
356	material, compound, mixture, or preparation which contains any quantity of
357	Phenylacetone.
358	(B) Some of these substances may be known by trade or other names:
359	phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
360	(vi) Nabilone, another name for nabilone: (±
361	)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
362	6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
363	(vii) A drug product or preparation that contains any component of marijuana,
364	including tetrahydrocannabinol, and is approved by the United States Food and
365	Drug Administration and scheduled by the Drug Enforcement Administration in
366	Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
367	(c) Schedule III:
368	(i) Unless specifically excepted or unless listed in another schedule, any material,
369	compound, mixture, or preparation which contains any quantity of the following
370	substances having a stimulant effect on the central nervous system, including its

371	salts, isomers whether optical, position, or geometric, and salts of the isomers
372	when the existence of the salts, isomers, and salts of isomers is possible within the
373	specific chemical designation:
374	(A) Those compounds, mixtures, or preparations in dosage unit form containing
375	any stimulant substances listed in Schedule II, which compounds, mixtures, or
376	preparations were listed on August 25, 1971, as excepted compounds under
377	Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other
378	drug of the quantitive composition shown in that list for those drugs or which
379	is the same except that it contains a lesser quantity of controlled substances;
380	(B) Benzphetamine;
381	(C) Chlorphentermine;
382	(D) Clortermine; and
383	(E) Phendimetrazine.
384	(ii) Unless specifically excepted or unless listed in another schedule, any material,
385	compound, mixture, or preparation which contains any quantity of the following
386	substances having a depressant effect on the central nervous system:
387	(A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
388	pentobarbital, or any salt of any of them, and one or more other active
389	medicinal ingredients which are not listed in any schedule;
390	(B) Any suppository dosage form containing amobarbital, secobarbital, or
391	pentobarbital, or any salt of any of these drugs which is approved by the United
392	States Food and Drug Administration for marketing only as a suppository;
393	(C) Any substance which contains any quantity of a derivative of barbituric acid
394	or any salt of any of them;
395	(D) Chlorhexadol;
396	(E) Buprenorphine;
397	(F) Any drug product containing gamma hydroxybutyric acid, including its salts,
398	isomers, and salts of isomers, for which an application is approved under the
399	federal Food, Drug, and Cosmetic Act, Section 505;
400	(G) Ketamine, its salts, isomers, and salts of isomers, some other names for
401	ketamine: ± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
402	(H) Lysergic acid;
403	(I) Lysergic acid amide;
404	(J) Methyprylon;

405	(K) Sulfondiethylmethane;
406	(L) Sulfonethylmethane;
407	(M) Sulfonmethane; and
408	(N) Tiletamine and zolazepam or any of their salts, some trade or other names for
409	a tiletamine-zolazepam combination product: Telazol, some trade or other
410	names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade
411	or other names for zolazepam:
412	4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
413	[1,4]-diazepin-7(1H)-one, flupyrazapon.
414	(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
415	a U.S. Food and Drug Administration approved drug product, some other names
416	for dronabinol:
417	(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,
418	or (-)-delta-9-(trans)-tetrahydrocannabinol.
419	(iv) Nalorphine.
420	(v) Unless specifically excepted or unless listed in another schedule, any material,
421	compound, mixture, or preparation containing limited quantities of any of the
422	following narcotic drugs, or their salts calculated as the free anhydrous base or
423	alkaloid:
424	(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
425	milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
426	alkaloid of opium;
427	(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
428	milligrams per dosage unit, with one or more active non-narcotic ingredients in
429	recognized therapeutic amounts;
430	(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
431	more than 15 milligrams per dosage unit, with a fourfold or greater quantity of
432	an isoquinoline alkaloid of opium;
433	(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
434	more than 15 milligrams per dosage unit, with one or more active, non-narcotic
435	ingredients in recognized therapeutic amounts;
436	(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
437	than 90 milligrams per dosage unit, with one or more active non-narcotic
438	ingredients in recognized therapeutic amounts;

439	(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
440	than 15 milligrams per dosage unit, with one or more active, non-narcotic
441	ingredients in recognized therapeutic amounts;
442	(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
443	or not more than 25 milligrams per dosage unit, with one or more active,
444	non-narcotic ingredients in recognized therapeutic amounts; and
445	(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
446	with one or more active, non-narcotic ingredients in recognized therapeutic
447	amounts.
448	(vi) Unless specifically excepted or unless listed in another schedule, anabolic
449	steroids including any of the following or any isomer, ester, salt, or derivative of
450	the following that promotes muscle growth:
451	(A) Boldenone;
452	(B) Chlorotestosterone (4-chlortestosterone);
453	(C) Clostebol;
454	(D) Dehydrochlormethyltestosterone;
455	(E) Dihydrotestosterone (4-dihydrotestosterone);
456	(F) Drostanolone;
457	(G) Ethylestrenol;
458	(H) Fluoxymesterone;
459	(I) Formebulone (formebolone);
460	(J) Mesterolone;
461	(K) Methandienone;
462	(L) Methandranone;
463	(M) Methandriol;
464	(N) Methandrostenolone;
465	(O) Methenolone;
466	(P) Methyltestosterone;
467	(Q) Mibolerone;
468	(R) Nandrolone;
469	(S) Norethandrolone;
470	(T) Oxandrolone;
471	(U) Oxymesterone;
472	(V) Oxymetholone:

473	(W) Stanolone;
474	(X) Stanozolol;
475	(Y) Testolactone;
476	(Z) Testosterone; and
477	(AA) Trenbolone.
478	(vii) Anabolic steroids expressly intended for administration through implants to
479	cattle or other nonhuman species, and approved by the Secretary of Health and
480	Human Services for use, may not be classified as a controlled substance.
481	(viii) A drug product or preparation that contains any component of marijuana,
482	including tetrahydrocannabinol, and is approved by the United States Food and
483	Drug Administration and scheduled by the Drug Enforcement Administration in
484	Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
485	(ix) Nabiximols.
486	(d) Schedule IV:
487	(i) Unless specifically excepted or unless listed in another schedule, any material,
488	compound, mixture, or preparation containing not more than 1 milligram of
489	difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or
490	any salts of any of them.
491	(ii) Unless specifically excepted or unless listed in another schedule, any material,
492	compound, mixture, or preparation which contains any quantity of the following
493	substances, including its salts, isomers, and salts of isomers when the existence of
494	the salts, isomers, and salts of isomers is possible within the specific chemical
495	designation:
496	(A) Alprazolam;
497	(B) Barbital;
498	(C) Bromazepam;
499	(D) Butorphanol;
500	(E) Camazepam;
501	(F) Carisoprodol;
502	(G) Chloral betaine;
503	(H) Chloral hydrate;
504	(I) Chlordiazepoxide;
505	(J) Clobazam;
506	(K) Clonazepam;

507	(L) Clorazepate;
508	(M) Clotiazepam;
509	(N) Cloxazolam;
510	(O) Delorazepam;
511	(P) Diazepam;
512	(Q) Dichloralphenazone;
513	(R) Estazolam;
514	(S) Ethchlorvynol;
515	(T) Ethinamate;
516	(U) Ethyl loflazepate;
517	(V) Fludiazepam;
518	(W) Flunitrazepam;
519	(X) Flurazepam;
520	(Y) Halazepam;
521	(Z) Haloxazolam;
522	(AA) Ketazolam;
523	(BB) Loprazolam;
524	(CC) Lorazepam;
525	(DD) Lormetazepam;
526	(EE) Mebutamate;
527	(FF) Medazepam;
528	(GG) Meprobamate;
529	(HH) Methohexital;
530	(II) Methylphenobarbital (mephobarbital);
531	(JJ) Midazolam;
532	(KK) Nimetazepam;
533	(LL) Nitrazepam;
534	(MM) Nordiazepam;
535	(NN) Oxazepam;
536	(OO) Oxazolam;
537	(PP) Paraldehyde;
538	(QQ) Pentazocine;
539	(RR) Petrichloral;
540	(SS) Phenobarbital;

541	(TT) Pinazepam;
542	(UU) Prazepam;
543	(VV) Quazepam;
544	(WW) Temazepam;
545	(XX) Tetrazepam;
546	(YY) Tramadol;
547	(ZZ) Triazolam;
548	(AAA) Zaleplon; and
549	(BBB) Zolpidem.
550	(iii) Any material, compound, mixture, or preparation of fenfluramine which contains
551	any quantity of the following substances, including its salts, isomers whether
552	optical, position, or geometric, and salts of the isomers when the existence of the
553	salts, isomers, and salts of isomers is possible.
554	(iv) Unless specifically excepted or unless listed in another schedule, any material,
555	compound, mixture, or preparation which contains any quantity of the following
556	substances having a stimulant effect on the central nervous system, including its
557	salts, isomers whether optical, position, or geometric isomers, and salts of the
558	isomers when the existence of the salts, isomers, and salts of isomers is possible
559	within the specific chemical designation:
560	(A) Cathine ((+)-norpseudoephedrine);
561	(B) Diethylpropion;
562	(C) Fencamfamine;
563	(D) Fenproprex;
564	(E) Mazindol;
565	(F) Mefenorex;
566	(G) Modafinil;
567	(H) Pemoline, including organometallic complexes and chelates thereof;
568	(I) Phentermine;
569	(J) Pipradrol;
570	(K) Sibutramine; and
571	(L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
572	(v) Unless specifically excepted or unless listed in another schedule, any material,
573	compound, mixture, or preparation which contains any quantity of
574	dextropropoxyphene (alpha-(+)-4-dimethylamino-1,

575	2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
576	(vi) A drug product or preparation that contains any component of marijuana and is
577	approved by the United States Food and Drug Administration and scheduled by
578	the Drug Enforcement Administration in Schedule IV of the federal Controlled
579	Substances Act, Title II, P.L. 91-513.
580	(e) Schedule V:
581	(i) Any compound, mixture, or preparation containing any of the following limited
582	quantities of narcotic drugs, or their salts calculated as the free anhydrous base or
583	alkaloid, which includes one or more non-narcotic active medicinal ingredients in
584	sufficient proportion to confer upon the compound, mixture, or preparation
585	valuable medicinal qualities other than those possessed by the narcotic drug alone:
586	(A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
587	(B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
588	grams;
589	(C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
590	grams;
591	(D) not more than 2.5 milligrams of diphenoxylate and not less than 25
592	micrograms of atropine sulfate per dosage unit;
593	(E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
594	(F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
595	atropine sulfate per dosage unit; and
596	(G) unless specifically exempted or excluded or unless listed in another schedule,
597	any material, compound, mixture, or preparation which contains Pyrovalerone
598	having a stimulant effect on the central nervous system, including its salts,
599	isomers, and salts of isomers.
600	(ii) A drug product or preparation that contains any component of marijuana,
601	including cannabidiol, and is approved by the United States Food and Drug
602	Administration and scheduled by the Drug Enforcement Administration in
603	Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.
604	(iii) Gabapentin.
605	Section 2. Repealer.
606	This bill repeals:
607	Section 4-45-101, Title.
608	Section 4-45-102, Definitions.

609	Section 4-45-103, Factual basis for claim as kratom product required Administrative
610	penalty Request for hearing.
611	Section 4-45-104, Kratom processor requirements Criminal penalty.
612	Section 4-45-105, Prohibition on sale to minors Criminal penalty.
613	Section 4-45-106, Civil action available.
614	Section 4-45-107, Rulemaking.
615	Section 4-45-108, Registration of kratom products Department duties.
616	Section 3. Effective Date.
617	This bill takes effect on May 6, 2026.